Breakthrough findings in the clinical and preclinical development of tuberculosis (TB)
vaccines have galvanized the field and suggest, for the first time since the development of …

Better understanding of the immunological components and their interactions necessary to
prevent or control Mycobacterium tuberculosis (Mtb) infection in humans is critical for …

There is an urgent need for new and better vaccines against tuberculosis (TB). Current
vaccine design strategies are generally focused on the enhancement of cell-mediated …

Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) is one of the most important
infectious diseases globally. Immune effector mechanisms that lead to protection or …

Inoculation of plasmid DNA, encoding an immunogenic protein gene of an infectious agent,
stands out as a novel approach for developing new generation vaccines for prevention of …

Currently there are a dozen or so of new vaccine candidates in clinical trials for prevention of
tuberculosis (TB) and each formulation attempts to elicit protection by enhancement of cell …

Historically, pharmaceutical aerosols have been employed for the treatment of obstructive
airway diseases, such as asthma and chronic obstructive pulmonary disease, but in the past …

Protein subunit vaccines, lacking pathogen-associated molecular patterns that trigger
immune responses, rely on adjuvants to induce robust immune responses against the target …

Accumulating evidence has documented a role for B cells and antibodies (Abs) in the
immunity against Mycobacterium tuberculosis (Mtb). Passive transfer studies with …

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide. Global research
efforts to improve TB control are hindered by insufficient understanding of the role that …